Compare Hewlett Packard Enterprise Co (HPE) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hewlett Packard Enterprise Co vs Viatris Inc — how do they compare? Hewlett Packard Enterprise Co trades at $48.92 (market cap $59.01B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Hewlett Packard Enterprise Co is far larger — about 3× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| HPE | VTRS | |
|---|---|---|
Market Cap | $59.01B | $19.79B |
Sector | Technology | Health |
52-Week High | $56.14 | $17.39 |
52-Week Low | $19.81 | $8.74 |
Enterprise Value | $74.96B | $32.00B |
Dividend Yield | 1.28% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPE trades at $46.73, up 1.99% today, with a bullish technical signal and strong recent earnings beats. The stock is supported by a $6.3 billion AI backlog and a strategic shift toward high-margin networking, which now drives 44% of segment profit. Revenue grew to $34.3 billion in 2025, though net income fell sharply to $57 million due to heavy investment. Analysts maintain a consensus price target of $69.69, implying significant upside.
Outlook is positive given AI infrastructure demand and networking momentum, but risks include execution on large investments, competitive pressures, and volatile cash flows. The stock offers growth potential if margin expansion continues, yet investors must monitor debt levels and earnings consistency amid macroeconomic uncertainty.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
